ReviewJournal of clinical medicine2020
Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma.
Review in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 16 citations in OpenAlex.
- A case of hepatitis B virus reactivation after elranatamab therapy in a patient with multiple myeloma.Journal of pharmaceutical health care and sciences · 2025Article
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages.Blood cancer journal · 2024Article
- Development of a Bispecific IgG1 Antibody Targeting BCMA and PDL1.Antibodies (Basel, Switzerland) · 2024Article
- Good Cop, Bad Cop: Profiling the Immune Landscape in Multiple Myeloma.Biomolecules · 2023Review
- Review
- Targeting the Microenvironment for Treating Multiple Myeloma.International journal of molecular sciences · 2022Review
- Innovation in BCMA CAR-T therapy: Building beyond the Model T.Frontiers in oncology · 2022Review
- Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma.Journal of clinical medicine · 2021Review
- Review
- Novel Experimental Drugs for Treatment of Multiple Myeloma.Journal of experimental pharmacology · 2021Review
- Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma.Frontiers in oncology · 2021Review
- Immunotherapy in Acute Myeloid Leukemia: Where We Stand.Frontiers in oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
B-cell maturation antigen (BCMA), a member of the tumor necrosis factor receptor superfamily, is universally expressed by normal and neoplastic plasma cells and plays a critical role in the proliferation, survival and tumor progression in multiple myeloma (MM). B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) have been recognized as proliferation ligands for BCMA in the bone marrow microenvironment. Soluble BCMA levels in the serum correlates with disease phase and tumor burden and is a predictor of progression-free survival (PFS) and overall survival (OS). Recently, the introduction of new monoclonal antibodies against CD38 (Daratumumab and Isatuximab) and SLAM7 (Elotuzumab) has changed the therapeutic approach to MM, improving the response rate and the time to progression, both in newly diagnosed and refractory/relapsed patients. Among the surface antigens on MM cells, BCMA is a suitable target for the design of new antibody-based strategies. Experimental approaches targeting BCMA are currently being investigated and include antibody-drug conjugates (ADCs), bispecific antibodies (bsAbs) and genetically engineered T-cells with chimeric antigen receptors (CAR). In this review we summarize the more recent findings about BCMA biologic rationale as a therapeutic target and report the updated results of preclinical and clinical studies focused on ADCs and bsAbs targeting BCMA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.